Pre-analytic factors and initial biomarker levels in community-acquired pneumonia patients

BMC Anesthesiology

Volumn 14, Issue 1, 2014, Pages

  Kutz, Alexander ^a   Grolimund, Eva ^a   Christ Crain, Mirjam ^b   Thomann, Robert ^c   Falconnier, Claudine ^d   Hoess, Claus ^e   Henzen, Christoph ^f   Zimmerli, Werner ^d   Mueller, Beat ^a   Schuetz, Philipp ^a   Wolbers, Marcel ^g   Widmer, Isabelle ^g   Neidert, Stefanie ^g   Fricker, Thomas ^g   Blum, Claudine ^g   Schild, Ursula ^g   Regez, Katharina ^g   Bossart, Rita ^g   Schoenenberger, Ronald ^g   Bucher, Heiner C ^g   Chaudri, A Ayesha ^g   Haeuptle, Jeannine ^g   Zarbosky, Roya ^g   Fiumefreddo, Rico ^g   Wieland, Melanie ^g   Nusbaumer, Charly ^g   Christ, Andres ^g   Bingisser, Roland ^g   Schneider, Kristian ^g   Vincenzi, Christine ^g   Kleinknecht, Michael ^g   Walz, Brigitte ^g   Briner, Verena ^g   Conen, Dieter ^g   Huber, Andreas ^g   Staehelin, Jody ^g   Bruehlhardt, Chantal ^g   Luginbuehl, Ruth ^g   Muehlemann, Agnes ^g   lambinon, Ineke ^g   Zueger, Max ^g   Marlowe, Robert J ^g   more..

^a University Department of Medicine   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c Burgerspital Solothurn   (Switzerland)

^d University Medical Clinic Liestal   (Switzerland)

^e Kantonsspital Muensterlingen   (Switzerland)

^f LUZERNER KANTONSSPITAL   (Switzerland)

^g Spencer Fontayne Corporation   (United States)

Author keywords

Blood biomarkers; C reactive protein; Community acquired pneumonia; Copeptin; Pre analytic factors; Pretreatment; Proadrenomedullin; Procalcitonin; White blood cells count

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; COPEPTIN; CORTICOSTEROID; PROADRENOMEDULLIN; PROCALCITONIN; ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; GLUCOCORTICOID;

ADULT; AGE DISTRIBUTION; AGED; ANTIBIOTIC THERAPY; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ASSESSMENT; COMMUNITY ACQUIRED PNEUMONIA; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; EMERGENCY WARD; FEMALE; GROUPS BY AGE; HUMAN; KIDNEY FUNCTION; LEUKOCYTE COUNT; LIVER FAILURE; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; SECONDARY ANALYSIS; SEX DIFFERENCE; ALGORITHM; BLOOD; CLINICAL TRIAL; COMMUNITY-ACQUIRED INFECTIONS; EMERGENCY HEALTH SERVICE; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PNEUMONIA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALGORITHMS; ANTI-BACTERIAL AGENTS; BIOLOGICAL MARKERS; COMMUNITY-ACQUIRED INFECTIONS; EMERGENCY SERVICE, HOSPITAL; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PNEUMONIA; PROSPECTIVE STUDIES; REGRESSION ANALYSIS;

EID: 84924030241     PISSN: None     EISSN: 14712253     Source Type: Journal    
DOI: 10.1186/1471-2253-14-102     Document Type: Article

References (34)

1. Woodhead M, Blasi F, Ewig S, Garau J, Huchon M, Leven M, Ortqvist A, Schaberg T, Torres A, Read R, Verheij TJM: Guidelines for the management of adult lower respiratory tract infections. Clin Microbiol Infect 2011,17(Suppl. 6):E1-E59.
2. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003,31(4):1250-1256. 10.1097/01.CCM.0000050454.01978.3B
3. Schuetz P, Briel M, Mueller B: Clinical outcomes associated with procalcitonin algorithms to guide antibiotic therapy in respiratory tract infections. JAMA 2013,309(7):717-718. 10.1001/jama.2013.697
4. Schuetz P, Briel M, Christ-Crain M, Stolz D, Bouadma L, Wolff M, Luyt CE, Chastre J, Tubach F, Kristoffersen KB, Wei L, Burkhardt O, Welte T, Schroeder S, Nobre V, Tamm M, Bhatnagar N, Bucher HC, Mueller B: Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis 2012,55(5):651-662. 10.1093/cid/cis464
5. Christ-Crain M, Muller B: Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J 2007,30(3):556-573. 10.1183/09031936.00166106
6. Schuetz P, Litke A, Albrich WC, Mueller B: Blood biomarkers for personalized treatment and patient management decisions in community-acquired pneumonia. Curr Opin Infect Dis 2013,26(2):159-167.
7. Kolditz M, Ewig S, Hoffken G: Management-based risk prediction in community-acquired pneumonia by scores and biomarkers. Eur Respir J 2013,41(4):974-984. 10.1183/09031936.00104412
8. Albrich WC, Ruegger K, Dusemund F, Schuetz P, Arici B, Litke A, Blum CA, Bossart R, Regez K, Schild U, Guglielmetti M, Conca A, Schafer P, Schubert M, de Geest S, Reutlinger B, Irani S, Burgi U, Huber A, Muller B: Biomarker-enhanced triage in respiratory infections - a proof-of-concept feasibility trial. Eur Respir J 2013,42(4):1064-1075. 10.1183/09031936.00113612
9. Schuetz P, Wolbers M, Christ-Crain M, Thomann R, Falconnier C, Widmer I, Neidert S, Fricker T, Blum C, Schild U, Morgenthaler NG, Schoenenberger R, Henzen C, Bregenzer T, Hoess C, Krause M, Bucher HC, Zimmerli W, Mueller B: Prohormones for prediction of adverse medical outcome in community-acquired pneumonia and lower respiratory tract infections. Crit Care 2010,14(3):R106. 10.1186/cc9055
10. Guertler C, Wirz B, Christ-Crain M, Zimmerli W, Mueller B, Schuetz P: Inflammatory responses predict long-term mortality risk in community-acquired pneumonia. Eur Respir J 2011,37(6):1439-1446. 10.1183/09031936.00121510
11. Kruger S, Ewig S, Kunde J, Hartmann O, Marre R, Suttorp N, Welte T, CAPNETZ study group: Assessment of inflammatory markers in patients with community-acquired pneumonia-influence of antimicrobial pre-treatment: results from the German competence network CAPNETZ. Clin Chim Acta 2010,411(23-24):1929-1934.
12. Seam N, Meduri GU, Wang H, Nylen ES, Sun J, Schultz MJ, Tropea M, Suffredini AF: Effects of methylprednisolone infusion on markers of inflammation, coagulation, and angiogenesis in early acute respiratory distress syndrome. Crit Care Med 2012,40(2):495-501. 10.1097/CCM.0b013e318232da5e
13. Meduri GU, Golden E, Freire AX, Taylor E, Zaman M, Carson SJ, Gibson M, Umberger R: Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest 2007,131(4):954-963. 10.1378/chest.06-2100
14. de Kruif MD, Lemaire LC, Giebelen IA, Struck J, Morgenthaler NG, Papassotiriou J, Elliott PJ, van der Poll T: The influence of corticosteroids on the release of novel biomarkers in human endotoxemia. Intensive Care Med 2008,34(3):518-522. 10.1007/s00134-007-0955-x
15. Morgenthaler NG, Struck J, Alonso C, Bergmann A: Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem 2005,51(10):1823-1829. 10.1373/clinchem.2005.051110
16. Morgenthaler NG, Struck J, Alonso C, Bergmann A: Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006,52(1):112-119. 10.1373/clinchem.2005.060038
17. Caruhel P, Mazier C, Kunde J, Morgenthaler NG, Darbouret B: Homogeneous time-resolved fluoroimmunoassay for the measurement of midregional proadrenomedullin in plasma on the fully automated system B.R.A.H.M.S KRYPTOR. Clin Biochem 2009,42(7-8):725-728.
18. Kruger S, Ewig S, Kunde J, Hanschmann A, Marre R, Suttorp N, Welte T: C-terminal provasopressin (copeptin) in patients with community-acquired pneumonia-influence of antibiotic pre-treatment: results from the German competence network CAPNETZ. J Antimicrob Chemother 2009,64(1):159-162. 10.1093/jac/dkp148
19. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, Neidert S, Fricker T, Blum C, Schild U, Regez K, Schoenenberger R, Henzen C, Bregenzer T, Hoess C, Krause M, Bucher HC, Zimmerli W, Mueller B: Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009,302(10):1059-1066. 10.1001/jama.2009.1297
20. Schuetz P, Christ-Crain M, Wolbers M, Schild U, Thomann R, Falconnier C, Widmer I, Neidert S, Blum CA, Schonenberger R, Henzen C, Bregenzer T, Hoess C, Krause M, Bucher HC, Zimmerli W, Müller B, ProHOSP study group: Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial. BMC Health Serv Res 2007, 7:102. 10.1186/1472-6963-7-102
21. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, Muller B: Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004,363(9409):600-607. 10.1016/S0140-6736(04)15591-8
22. Terzic D, Johansson-Fällgren AS, Ragnarsson O, Goetze JP, Hammarsten O: Evaluation of a sensitive copeptin assay for clinical measurement. Open Clin Chem J 2012, 5:21-26. 10.2174/1874241601205010021
23. Muller B, Peri G, Doni A, Perruchoud AP, Landmann R, Pasqualini F, Mantovani A: High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration. J Leukoc Biol 2002,72(4):643-649.
24. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN: A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997,336(4):243-250. 10.1056/NEJM199701233360402
25. Albrich WC, Dusemund F, Ruegger K, Christ-Crain M, Zimmerli W, Bregenzer T, Irani S, Buergi U, Reutlinger B, Mueller B, Schuetz P: Enhancement of CURB65 score with proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: derivation of a clinical algorithm. BMC Infect Dis 2011, 11:112. 10.1186/1471-2334-11-112
26. Schaaf B, Kruse J, Rupp J, Reinert RR, Droemann D, Zabel P, Ewig S, Dalhoff K: Sepsis severity predicts outcome in community-acquired pneumococcal pneumonia. Eur Respir J 2007,30(3):517-524. 10.1183/09031936.00021007
27. Bruns AH, Oosterheert JJ, Hak E, Hoepelman AI: Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia. Eur Respir J 2008,32(3):726-732. 10.1183/09031936.00003608
28. Muller F, Christ-Crain M, Bregenzer T, Krause M, Zimmerli W, Mueller B, Schuetz P, Pro HSG: Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest 2010,138(1):121-129. 10.1378/chest.09-2920
29. Metlay JP, Schulz R, Li YH, Singer DE, Marrie TJ, Coley CM, Hough LJ, Obrosky DS, Kapoor WN, Fine MJ: Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med 1997,157(13):1453-1459. 10.1001/archinte.1997.00440340089009
30. Meisner M, Schmidt J, Huttner H, Tschaikowsky K: The natural elimination rate of procalcitonin in patients with normal and impaired renal function. Intensive Care Med 2000,26(Suppl 2):S212-S216.
31. Meisner M, Huttemann E, Lohs T, Kasakov L, Reinhart K: Elimination of procalcitonin and plasma concentrations during continuous veno-venous haemodiafiltration in septic patients. Eur J Anaesthesiol 2000,17(11):665-671. 10.1046/j.1365-2346.2000.00758.x
32. Meisner M, Lohs T, Huettemann E, Schmidt J, Hueller M, Reinhart K: The plasma elimination rate and urinary secretion of procalcitonin in patients with normal and impaired renal function. Eur J Anaesthesiol 2001,18(2):79-87. 10.1046/j.0265-0215.2000.00783.x
33. Meisner M, Huttemann E, Lohs T, Kasakov L, Reinhart K: Plasma concentrations and clearance of procalcitonin during continuous veno-venous hemofiltration in septic patients. Shock 2001,15(3):171-175. 10.1097/00024382-200115030-00002
34. Elefsiniotis IS, Skounakis M, Vezali E, Pantazis KD, Petrocheilou A, Pirounaki M, Papatsibas G, Kontou-Kastellanou C, Moulakakis A: Clinical significance of serum procalcitonin levels in patients with acute or chronic liver disease. Eur J Gastroenterol Hepatol 2006,18(5):525-530. 10.1097/00042737-200605000-00012